Clinical Trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing. The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Protocol Amendment History 3 changes
notable Trial sites expanded: 133 -> 136 locations 2026-07-14
notable Trial sites expanded: 127 -> 131 locations 2026-06-24
notable Trial sites expanded: 114 -> 117 locations 2026-04-03
Trial Details
NCT Number NCT06890884
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Lymphoma, Large B-Cell, Diffuse
Enrollment 594 participants
Start Date 2025-04-11
Primary Completion 2027-12-13 (estimated)
Study Completion 2032-12-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-07